Gene patenting and licensing: The role of academic researchers and advocacy groups

Genetics in Medicine

Volumn 10, Issue 5, 2008, Pages 314-319

  Ledbetter, David H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bayh Dole Act; Gene patents; Genetic testing; Licensing models

Indexed keywords

COMMERCIAL SPECIES; DIAGNOSTIC TEST; FUNDING; GENE; GENETIC ANALYSIS; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HUMAN; HUMAN GENETICS; LABORATORY TEST; LICENSING; MANAGER; MEDICAL GENETICS; MEDICAL SOCIETY; NOTE; PATENT; PATIENT RIGHT; UNITED STATES;

EID: 44449124733     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181729dab     Document Type: Note

References (15)

1. Crichton M. Next. New York: Harper Collins; 2006.
2. Caulfield T, Bubela T, Murdoch CJ. Myriad and the mass media: the covering of a gene patent controversy. Genet Med 2007;9:850-855.
3. Walsh R, Casadei S, Coats KH, Swisher E, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295:1379-1388.
4. Cho MK, Illangasekare S, Weaver MA, Leonard DGB, et al. Effects of patents and licenses on the provision of clinical genetic testing services. J Mol Diagn 2003;5:3-8.
5. Verbeure B, Matthijs G, Van Overwalle G. Analysing DNA patents in relation with diagnostic genetic testing. Eur J Hum Gen 2006;14:26-33.
6. National Academy of Sciences (NAS). Reaping the benefits of genomic and proteomic research, intellectual property rights, innovation and public health. Washington, DC: NAS, 2006.
7. Jensen K, Murray F. Intellectual property landscape of the human genome. Science 2005;310:239-240.
8. Hopkins JJ, Mahdi S, Patel P, Thomas SM. DNA patenting: the end of an era? Nat Biotechnol 2007;25:185-187.
9. Pressman L, Burgess R, Cook-Deegan RM, McCormack SJ, et al. The licensing of DNApatents by US academic institutions: an empirical survey. Nat Biotechnol 2006;24:31-39.
10. National Institutes of Health (NIH). Best practices for the licensing of genomic inventions. Federal Register 2005;70:18410-18415.
11. Matthijs G. The European opposition against the BRCA gene patents. Fam Cancer 2006;5:95-102.
12. Klein RD. Gene patents and genetic testing in the United States. Nat Biotechnol 2007;25:989-990.
13. Amir RE, Van den Veyer IB, Wan M, Tran CQ, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Gen 1999;23:185-188.
14. Mnatzakanian GN, Lohi H, Munteanu I, Alfred SE, et al. A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome. Nat Gen 2004;36:339-341.
15. Terry SF, Terry PF, Rauen KA, Uitto J, et al. Advocacy groups as research organizations: the PXE International example. Nat Rev Gen 2007;8:157-164.